Aerovate Therapeutics Quote - AVTE

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.58

Bid

1.58

Ask

1.60

Volume

4,811,014

1.25 Day's Range 1.46

0.00 52 Week Range 0.00

Market Cap

40.397M

Previous Close

1.41

Open

1.36

Last Trade

1.6

Last Trade Time

Financial Volume

US$ 6,324,824

VWAP

1.3147

Average Volume (3m)

Shares Outstanding

27,668,887

Dividend Yield

PE Ratio

-0.53

Earnings Per Share (EPS)

-2.73

Revenue

Net Profit

-75.52M

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hyper... Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.aerovatetx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Aerovate Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVTE. The last closing price for Aerovate Therapeutics was US$1.41. Over the last year, Aerovate Therapeutics shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Aerovate Therapeutics currently has 27,668,887 shares outstanding. The market capitalization of Aerovate Therapeutics is US$40.40 million. Aerovate Therapeutics has a price to earnings ratio (PE ratio) of -0.53.

Form 8-K - Current report

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GRCGold Springs Resource Corp	$ 0.09 (20.00%)	255.2k
SFDNXT Energy Solutions Inc	$ 0.16 (18.52%)	118k
SAMStarcore International Mines Ltd	$ 0.14 (16.67%)	525
DSVDiscovery Silver Corp	$ 1.03 (13.19%)	913.48k
PYRPyroGenesis Canada Inc	$ 0.69 (13.11%)	191.75k
CFXCanfor Pulp Products Inc	$ 1.04 (-25.71%)	141.77k
AEZSAeterna Zentaris Inc	$ 6.04 (-24.50%)	14.45k
LPENLoop Energy Inc	$ 0.025 (-16.67%)	15.04k
ETEvertz Technologies Ltd	$ 13.30 (-13.30%)	120.44k
AABAberdeen International Inc	$ 0.035 (-12.50%)	1.61M
CNQCanadian Natural Resources Ltd	$ 47.87 (1.36%)	29.03M
TRPTC Energy Corporation	$ 52.25 (-0.08%)	14.09M
SUSuncor Energy Inc	$ 50.82 (0.08%)	8.95M
MFCManulife Financial Corporation	$ 35.23 (0.46%)	7.75M
POWPower Corp of Canada	$ 37.57 (-0.71%)	6.65M